Particle.news
Download on the App Store
4 ARTICLES
·
last mo.

Moderna’s Combined COVID-19 and Flu Vaccine Shows Promising Phase III Results

Phase III trial data published in JAMA confirms the vaccine's safety and efficacy, but regulatory approval and strain updates are pending.

Die Auffrischimpfung gegen COVID-19 gilt weiterhin als wichtig für Risikogruppen
Image
Image
Image

Overview

  • The combined mRNA-1083 vaccine demonstrated immune responses at least as strong as, and in some cases superior to, separate COVID-19 and flu vaccines in adults over 50.
  • Phase III trial results, involving approximately 8,000 participants, were published in the Journal of the American Medical Association on May 7, 2025.
  • The vaccine showed a stronger immune response against influenza A, comparable response against influenza B, and at least equal response to SARS-CoV-2 compared to existing vaccines.
  • No serious adverse events were observed, with mild side effects similar to those of standard individual vaccines.
  • Regulatory approval, strain adaptation, and a recommendation from Germany’s Ständige Impfkommission (Stiko) are required before the vaccine can be widely deployed, with no confirmed rollout timeline yet.